Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma

被引:10
|
作者
Abulafia, O
Kleinhaus, K
Levi, G
Lee, YC
Sherer, DM
机构
[1] SUNY Hlth Sci Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Brooklyn, NY 11203 USA
[2] SUNY Hlth Sci Ctr, Dept Pathol, Brooklyn, NY 11203 USA
[3] Maimonides Hosp, Brooklyn, NY 11219 USA
[4] Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Dept Obstet & Gynecol, New York, NY 10032 USA
关键词
angiogenesis; uterine leiomyoma; gonadotropin-releasing hormone agonist therapy;
D O I
10.1159/000052953
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To assess the effect of gonadotropin-releasing hormone (GnRH)agonist treatment upon angiogenesis in uterine leiomyomata. Methods: Uterine leiomyomata specimens of 49 consecutive patients who underwent myomectomy or hysterectomy following presurgical treatment with (n = 23) and without (n = 26) GnRH agonist were stained immunohistochemically with antibody to factor VIII-related antigen. For each subject, age, parity, number of Lupron treatments, leiomyoma size (cm), and mean microvessel counts calculated from three fields (x400) were recorded. Differences in patient age, parity, microvessel counts and leiomyoma size between GnRH agonist treated and untreated patients were tested by unpaired Student's t test. Differences among the various number of doses were tested by one-way ANOVA, with Bonferonni and Neuman-Keuls post hoc tests between specific dose-number groups. The relationship between microvessel counts and leiomyoma size was tested by Pearson correlation test. Multivariate stepwise regression tested the relationship between the number of Lupron doses and microvessel counts, correcting for age, parity, and leiomyoma size. p < 0.05 was considered significant. Results: Patient age and parity were similar in GnRH treated and untreated patients (mean 43.3 <plus/minus> 6.6 versus 43.9 +/- 7.5 years and median 2 (range 0-7) versus 1 (range 0-5), p = 0.78 and p = 0.45, respectively). Microvessel counts of leiomyomata specimens treated presurgically with GnRH agonist therapy (median 22.7, range 6.7-65.7) were not significantly different from microvessel counts of specimens without presurgical GnRH agonist treatment (median 19.8, range 6-53; p = 0.77). No correlation between leiomyoma size and microvessel counts was noted (r = 0.06, P = 0.7). Conclusion: Angiogenesis as assessed by microvessel counts in surgically removed leiomyomata is not affected by presurgical medical management with GnRH agonist therapy. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:108 / 113
页数:6
相关论文
共 50 条
  • [41] TESTICULAR HISTOLOGY FOLLOWING CHRONIC GONADOTROPIN-RELEASING HORMONE AGONIST TREATMENT
    RAJFER, J
    SWERDLOFF, RS
    HEBER, DM
    FERTILITY AND STERILITY, 1984, 42 (05) : 765 - 771
  • [42] Sertraline in the treatment of depression associated with gonadotropin-releasing hormone agonist therapy
    Warnock, JK
    Bundren, JC
    Morris, DW
    BIOLOGICAL PSYCHIATRY, 1998, 43 (06) : 464 - 465
  • [43] Effect of gonadotropin-releasing hormone agonist treatment on growth hormone responses in women with polycystic ovary syndrome
    Villa, P
    De Marinis, L
    Mancini, A
    Guido, M
    Selvaggi, L
    Lanzone, A
    FERTILITY AND STERILITY, 2004, 82 (01) : 250 - 252
  • [44] Sperm to zona pellucida binding depends on the use of a gonadotropin-releasing hormone agonist or a gonadotropin-releasing hormone antagonist
    Schröder, AK
    Schöpper, B
    Al-Hasani, S
    Löning, M
    Diedrich, K
    Ludwig, M
    FERTILITY AND STERILITY, 2003, 79 (03) : 648 - 650
  • [45] USE OF A GONADOTROPIN-RELEASING HORMONE AGONIST TO MANAGE PERIMENOPAUSAL WOMEN WITH SYMPTOMATIC UTERINE MYOMAS
    Wang, Peng-Hui
    Lee, Wen-Ling
    Cheng, Ming-Huei
    Yen, Ming-Shyen
    Chao, Kuan-Chong
    Chao, Hsiang-Tai
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2009, 48 (02): : 133 - 137
  • [46] Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest
    Matsushima, Takashi
    Akira, Shigeo
    Yoneyama, Koichi
    Takeshita, Toshiyuki
    GYNECOLOGICAL ENDOCRINOLOGY, 2020, 36 (06) : 521 - 524
  • [47] EFFECT OF CHRONIC GONADOTROPIN-RELEASING HORMONE AGONIST THERAPY ON TESTICULAR STEROIDOGENESIS
    RAJFER, J
    SWERDLOFF, RS
    XIE, HW
    SIKKA, SC
    FERTILITY AND STERILITY, 1984, 42 (02) : 325 - 325
  • [48] THE EFFECT OF A GONADOTROPIN-RELEASING HORMONE AGONIST ANALOG (NAFARELIN) ON BONE METABOLISM
    JOHANSEN, JS
    RIIS, BJ
    HASSAGER, C
    MOEN, M
    JACOBSON, J
    CHRISTIANSEN, C
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 67 (04): : 701 - 706
  • [49] Model of gonadotropin-releasing hormone and gonadotropin-releasing hormone complex
    Wiwanitkit, Viroj
    SEXUALITY AND DISABILITY, 2006, 24 (03) : 175 - 178
  • [50] GONADOTROPIN-RELEASING-HORMONE AGONIST ANALOGS IN THE TREATMENT OF UTERINE LEIOMYOMAS
    ROCK, JA
    JOURNAL OF GYNECOLOGIC SURGERY, 1991, 7 (03) : 147 - 153